

Supplementary Online Content


Hedayati SS, Gregg LP, Carmody T, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. *JAMA*. doi:10.1001/jama.2017.17131

eFigure. Randomized double-blinded placebo-controlled trial of sertraline treatment of depression in patients with chronic kidney disease

eTable. Treatment efficacy endpoints at exit

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Randomized double-blinded placebo-controlled trial of sertraline treatment of depression in patients with chronic kidney disease



eTable. Treatment efficacy endpoints at exit

Endpoint	Sertraline (N = 97)	Placebo (N = 96)	Difference (95% CI)	P value
Primary Endpoint				
QIDS-C ₁₆ exit score, mean (95% CI) ^a				
Total cohort	9.9 (9.0, 10.7)	9.8 (9.0, 10.6)	0.0 (-1.1, 1.2)	0.96
Secondary Endpoints				
QIDS-C ₁₆ exit score, mean (95% CI) ^a				
CKD Stage 3 ^b	9.6 (8.2, 11.1)	9.3 (8.0, 10.6)	0.3 (-1.6, 2.2)	0.78
CKD Stage 4 ^b	9.7 (8.4, 11.0)	10.1 (9.0, 11.3)	-0.4 (-2.1, 1.3)	0.64
CKD Stage 5 ^b	10.8 (8.8, 12.9)	10.5 (8.2, 12.8)	0.3 (-2.6, 3.3)	0.82
University and Parkland Site	10.3 (9.3, 11.4)	11.0 (9.7, 12.2)	-0.6 (-2.2, 1.0)	0.44
VA Site	9.4 (8.0, 10.8)	8.7 (7.7, 9.7)	0.7 (-1.0, 2.4)	0.41
WSAS exit score, mean (95% CI) ^c	14.2 (11.6, 16.8)	15.4 (12.5, 18.2)	-1.2 (-5.0, 2.7)	0.55
KDQOL-SF 1.3 exit score, median (IQR) ^d				
Kidney disease component				
Symptoms and Problems	77.2 (64.6, 87.5)	77.3 (63.6, 88.6)	0.0 (-4.5, 4.5)	0.96
Effects of Kidney Disease	75.0 (56.3, 87.5)	68.8 (53.1, 87.5)	3.1 (-5.4, 9.4)	0.58
Burden of Kidney Disease	50.0 (31.3, 81.3)	50.0 (31.3, 68.8)	6.2 (0.0, 18.8)	0.16
Work Status	0.0 (0.0, 50.0)	0.0 (0.0, 50.0)	0.0 (0.0, 0.0)	0.25
Cognitive Function	76.7 (53.3, 100.0)	80.0 (60.0, 100.0)	0.0 (-6.7, 6.7)	0.83
Quality of Social Interaction	73.3 (60.0, 86.7)	66.7 (53.3, 86.7)	0.0 (0.0, 6.7)	0.28
Sexual Function	50.0 (25.0, 100.0)	62.5 (37.5, 100.0)	0.0 (-25.0, 12.5)	0.78
Sleep	71.3 (55.0, 80.0)	58.8 (47.5, 70.0)	7.5 (2.5, 12.5)	0.02
Social Support	83.3 (50.0, 100.0)	66.7 (33.3, 83.3)	16.7 (0.0, 16.7)	0.01
Patient Satisfaction	83.3 (66.7, 83.3)	83.3 (50.0, 83.3)	0.0 (0.0, 0.0)	0.89
Physical functioning component				
Physical Functioning	40.0 (20.0, 65.0)	35.0 (15.0, 55.0)	5.0 (-5.0, 14.3)	0.27
Role Limits – Physical	25.0 (0.0, 75.0)	0.0 (0.0, 50.0)	0.0 (0.0, 0.0)	0.11
Pain	55.0 (32.5, 77.5)	55.0 (22.5, 67.5)	0.0 (-10.0, 10.0)	0.63
General Health	40.0 (20.0, 50.0)	30.0 (20.0, 45.0)	5.0 (-5.0, 10.0)	0.26
Mental functioning component				
Emotional Well-being	72.0 (56.0, 80.0)	68.0 (52.0, 84.0)	0.0 (-8.0, 4.0)	0.93
Role Limits - Emotional	66.7 (0.0, 100.0)	33.3 (0.0, 100.0)	0.0 (0.0, 0.0)	0.33

Social Function	62.5 (37.5, 87.5)	50.0 (37.5, 87.5)	0.0 (0.0, 12.5)	0.40
Energy	45.0 (25.0, 60.0)	40.0 (30.0, 60.0)	0.0 (-5.0, 10.0)	0.62
Overall Health	50.0 (40.0, 50.0)	50.0 (40.0, 50.0)	0.0 (0.0, 0.0)	0.48
SF-12 Physical Composite	32.7 (27.5, 41.1)	31.7 (25.9, 39.3)	1.7 (-1.2, 4.5)	0.24
SF-12 Mental Composite	45.2 (37.9, 51.7)	42.9 (35.5, 55.8)	0.2 (-3.6, 3.8)	0.89

^aQIDS-C₁₆ denotes the 16-item Quick Inventory of Depressive Symptomatology-Clinician rated scale (scores range from 0 to 27, with higher scores indicating a greater severity of depressive symptoms).

^bCKD is defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m².

^cWSAS, Work and Social Adjustment Scale.

^dKDQOL-SF 1.3, Kidney Disease Quality of Life Survey Version 1.3. Raw scores are transformed to a 0-100 scale, where higher numbers signify more favorable QOL.